Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc is currently positioned favorably within the pharmaceutical sector, particularly due to its focus on stenoparib, an oral inhibitor demonstrating promising and durable clinical benefits for patients with advanced recurrent ovarian cancer. The company’s proprietary Drug Response Predictor technology enhances patient selection, which is anticipated to improve clinical outcomes and support the overall efficacy of its treatment approach. Positive clinical data indicating a median overall survival exceeding 25 months in Phase 2 trials, combined with attractive valuation metrics, underscores the potential for significant upside, reflecting a robust outlook for the company's stock.

Bears say

Allarity Therapeutics Inc reported a net loss of $2.8 million with an earnings per share (EPS) of $(0.19), which was slightly better than previous estimates but still indicates ongoing financial challenges. The company faces significant risks, including liquidity concerns, potential failure of its drug candidates in clinical trials, and regulatory hurdles that could hinder commercialization efforts. Furthermore, external factors such as competition, reimbursement issues, and shifting investor sentiment toward biotech stocks contribute to a challenging outlook for the company's financial stability and growth potential.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.